KURA Stock Risk & Deep Value Analysis
Kura Oncology Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KURA Stock
We analyzed Kura Oncology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KURA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
KURA Risk Analysis & Red Flags
What Could Go Wrong
Kura Oncology's biggest risk is the failure of KOMZIFTI's commercial ramp-up. Despite strong market access, the Q4 2025 revenue massively missed estimates. If subsequent quarterly sales do not show significant acceleration, investor confidence will erode further, potentially leading to a cash crunch despite a healthy balance sheet, and necessitating highly dilutive future capital raises.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Significant Q4 2025 revenue miss ($17.34M actual vs $74.52M estimate)
- ⚠
Deeply negative profitability (TTM EPS -$3.18, ROE -94.82%) with high cash burn
- ⚠
Analyst price target cuts, indicating tempered expectations for commercialization timeline/magnitude
- ⚠
Delayed first-line sales potential (KOMET-017 topline 2028, sales to 2029)
Upcoming Risk Events
- 📅
Disappointing KOMZIFTI sales figures in upcoming earnings reports
- 📅
Negative or inconclusive data from H2 2026 ziftomenib combo trial
- 📅
Competitor entry or unexpected clinical trial success in the NPM1-mutant AML space
- 📅
Further delays in KOMET-017 Phase 3 trial or regulatory approval timelines
When to Reconsider
- 🚪
Exit if quarterly KOMZIFTI sales fail to show sequential growth for two consecutive quarters.
- 🚪
Sell if cash position drops below $200M without a clear path to profitability or near-term funding.
- 🚪
Reconsider if the H2 2026 combo data is negative or signals limited efficacy.
Unlock KURA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Kura Oncology Inc (KURA) Do?
Market Cap
$683.67M
Sector
Healthcare
Industry
Biotechnology
Employees
192
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Visit Kura Oncology Inc WebsiteInvestment Thesis
Kura Oncology presents a high-risk, high-reward opportunity driven by KOMZIFTI, the first FDA-approved menin inhibitor for NPM1-mutant AML. Despite an initial Q4 2025 revenue miss, strong market access and a robust cash position provide runway for a commercial ramp-up. Successful execution in expanding KOMZIFTI sales, positive combo therapy data in H2 2026, and a favorable outcome from the KOMET-017 Phase 3 trial could significantly de-risk the investment and propel the stock towards 10x growth by establishing market leadership in a critical unmet medical need.
Is KURA Stock Undervalued?
Unlock the full AI analysis for KURA
Get the complete DVR score, risk analysis, and more
KURA Price Targets & Strategy
12-Month Target
$18.00
Bull Case
$25.00
Bear Case
$6.00
Valuation Basis
Based on 19.8x P/S applied to estimated FY2026 revenue of $80M ($1.59B market cap / 88.5M shares outstanding = $18.00/share)
Entry Strategy
Dollar-cost average between $8-$10, looking for consolidation above the $8 support level. Consider initial entry on positive news regarding KOMZIFTI sales ramp or combo data.
Exit Strategy
Take 50% profit at $25, reconsider full exit if KOMZIFTI sales fail to accelerate significantly in 2026 or if key clinical trials disappoint. Stop loss at $6.50 (below recent lows).
Portfolio Allocation
5% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is KURA Financially Healthy?
Valuation
P/E Ratio
-2.73
Forward P/E
-3.53
Price/Book
3.91
Price/Sales
10.13
Profitability
Net Margin
-41.30%
Return on Equity
-54.21%
Revenue Growth
25.20%
EPS
$-3.18
Balance Sheet
Current Ratio
6.06
Quick Ratio
5.81
Debt/Equity
0.12
Cash & Equivalents
$646.78M
Other
Beta (Volatility)
0.25
Does KURA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property around ziftomenib as a first-in-class menin inhibitor for NPM1-mutant AML. Switching costs can develop as patients are successfully treated. The durability relies on successful pipeline development and establishing ziftomenib as the standard of care before competitors can bring similar drugs to market.
Moat Erosion Risks
- •Emergence of superior or equally effective menin inhibitors from competitors
- •Clinical trial failures for ziftomenib in broader indications (e.g., frontline AML)
- •Patent expiry or legal challenges to intellectual property
KURA Competitive Moat Analysis
Sign up to see competitive advantages
KURA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Retail investors are likely cautiously optimistic due to high analyst targets but concerned by recent earnings miss and price action.
Institutional Sentiment
Neutral-Negative. Recent analyst PT cuts (Mizuho, UBS) suggest a more conservative outlook, though 'Buy' ratings are maintained, indicating long-term belief in the asset despite short-term challenges.
Insider Activity (Form 4)
President and CEO Troy Edward Wilson exercised options for 6,103 shares at $6.15/share ($37,543 value) on Mar 23, 2026; no sale reported, indicating a positive signal of confidence in future value.
Options Flow
Normal options activity. No specific unusual call or put activity reported in real-time intelligence.
Earnings Intelligence
Next Earnings
2026-04-30
Surprise Probability
Medium
Historical Earnings Pattern
Likely to be highly sensitive to KOMZIFTI sales figures and commercial commentary, with significant stock price volatility on misses or beats.
Key Metrics to Watch
Competitive Position
Top Competitor
SYBX
Market Share Trend
Early in KOMZIFTI launch, aiming to gain significant share in relapsed/refractory NPM1-mutant AML. Market access (84%) is strong, but actual sales volume needs to improve significantly to gain ground.
Valuation vs Peers
Trading at a high P/S multiple (currently ~9-10x on an annualized Q4 basis, potentially 18-20x on forward estimates for growth) which is typical for early-stage commercial biotechs with a novel approved product, but requires significant growth to justify.
Competitive Advantages
- •First-in-class FDA-approved menin inhibitor (KOMZIFTI) for NPM1-mutant AML
- •Strong intellectual property protecting ziftomenib
- •High market access quickly achieved post-approval
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive KURA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on Apr 30, 2026 (focus on KOMZIFTI sales ramp)
- •H2 2026: Ziftomenib/gilteritinib combo data in relapsed/refractory NPM1/FLT3-mutated AML
Medium-Term (6-18 months)
- •Continued commercialization ramp-up of KOMZIFTI in relapsed/refractory NPM1-mutant AML (through 2027)
- •Potential Kyowa Kirin milestones up to $180M by early 2027
- •Expansion of KOMZIFTI into additional indications or geographies via partnerships
Long-Term (18+ months)
- •KOMET-017 Phase 3 topline data (2028) for first-line NPM1-mutant AML (potential approval 2029)
- •Establishment of ziftomenib as the standard of care in NPM1-mutant AML
- •Pipeline expansion beyond ziftomenib
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KURA?
- ✓
Acceleration in KOMZIFTI revenue growth in Q1 2026 and subsequent quarters
- ✓
Positive clinical data readouts for ziftomenib combination therapies
- ✓
Analyst upgrades and increased institutional ownership
Bull Case Analysis
See what could go right with Premium
Competing with KURA
See how Kura Oncology Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Kura Oncology Inc KURA | $683.7M | 5.5 | -2.7 | $83.3M | -41.3% | 25.2% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Kura Oncology Inc Makes Money
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for cancer. Its primary business model revolves around the research, development, and commercialization of small-molecule therapeutics. Currently, its main revenue driver is KOMZIFTI (ziftomenib), an FDA-approved drug for relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). The company generates revenue by selling KOMZIFTI, and potentially through milestone payments and royalties from licensing agreements for its pipeline assets, such as the agreement with Kyowa Kirin for global rights ex-US. The business relies heavily on successful clinical trials, regulatory approvals, and effective commercialization of its oncology drugs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Kura Oncology Inc (KURA)?
As of April 10, 2026, Kura Oncology Inc has a DVR Score of 5.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Kura Oncology Inc?
Kura Oncology Inc's market capitalization is approximately $683.7M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Kura Oncology Inc use?
KURA is the ticker symbol for Kura Oncology Inc. The company trades on the NMS.
What is the risk level for KURA stock?
Our analysis rates Kura Oncology Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of KURA?
Kura Oncology Inc currently has a price-to-earnings (P/E) ratio of -2.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Kura Oncology Inc's revenue growing?
Kura Oncology Inc has reported revenue growth of 25.2%. The company is showing strong top-line momentum.
Is KURA stock profitable?
Kura Oncology Inc has a profit margin of -41.3%. The company is currently unprofitable.
How often is the KURA DVR analysis updated?
Our AI-powered analysis of Kura Oncology Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 10, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KURA (Kura Oncology Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.